* Intra-Cellular Therapies Inc ITCI.OQ reported a
quarterly
adjusted loss of 16 cents per share for the quarter ended in
June, higher than the same quarter last year, when the company
reported EPS of -45 cents. The mean expectation of
fifteen analysts for the quarter was for a loss of 19 cents per
share. Wall Street expected results to range from -27 cents
to -10 cents per share.
* Revenue rose 45.7% to $161.39 million from a year ago;
analysts
expected $157.88 million.
* Intra-Cellular Therapies Inc's reported EPS for the
quarter was
a loss of 16 cents.
* The company reported a quarterly loss of $16.22 million.
* Intra-Cellular Therapies Inc shares had risen by 14.1%
this
quarter and gained 9.1% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by
about 4.4%
in the last three months.
* In the last 30 days, three analysts negatively revised
earnings
estimates
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 14 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the
pharmaceuticals
peer group is also "buy"
Wall Street's median 12-month price target for Intra-Cellular
Therapies Inc is $92.00
This summary was machine generated from LSEG data August 7 at
02:22 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Jun. 30 2024 -0.19 -0.16 Beat
Mar. 31 2024 -0.32 -0.16 Beat
Dec. 31 2023 -0.44 -0.30 Beat
Sep. 30 2023 -0.57 -0.25 Beat